Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
NSP de Campos, A de Oliveira Beserra… - International Journal of …, 2022 - mdpi.com
The complete regression of clear cell renal cell carcinoma (ccRCC) obtained pre-clinically
with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in
doses equivalent to≅ 108 CAR T cells/kg renewed the potential of this target to treat ccRCC
and other tumors in hypoxia. The immune checkpoint blockade (ICB) brought durable
clinical responses in advanced ccRCC and other tumors. Here, we tested CD8α/4-1BB
compared to CD28-based anti-CAIX CAR peripheral blood mononuclear cells (PBMCs) …
with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in
doses equivalent to≅ 108 CAR T cells/kg renewed the potential of this target to treat ccRCC
and other tumors in hypoxia. The immune checkpoint blockade (ICB) brought durable
clinical responses in advanced ccRCC and other tumors. Here, we tested CD8α/4-1BB
compared to CD28-based anti-CAIX CAR peripheral blood mononuclear cells (PBMCs) …
Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
C NSPd, B AdO, PHB Pereira, AS Chaves… - 2022 - europepmc.org
The complete regression of clear cell renal cell carcinoma (ccRCC) obtained pre-clinically
with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in
doses equivalent to 10e8 CAR T cells/Kg renewed the potential of this target to treat ccRCC
and other tumors in hypoxia. The immune checkpoint blockade (ICB) brought durable
clinical responses in advanced ccRCC and other tumors. Here we tested CD8/4-1BB
compared to CD28-based anti-CAIX CAR PBMCs cells-releasing anti-programmed cell …
with anti-carbonic anhydrase IX (CAIX) G36 chimeric antigen receptor (CAR) T cells in
doses equivalent to 10e8 CAR T cells/Kg renewed the potential of this target to treat ccRCC
and other tumors in hypoxia. The immune checkpoint blockade (ICB) brought durable
clinical responses in advanced ccRCC and other tumors. Here we tested CD8/4-1BB
compared to CD28-based anti-CAIX CAR PBMCs cells-releasing anti-programmed cell …
以上显示的是最相近的搜索结果。 查看全部搜索结果